Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.

MLA

Lv, Jingjing, et al. “Immunogenicity and Safety of Heterologous versus Homologous Prime-Boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine: A Systematic Review.” Infectious Diseases of Poverty, vol. 11, no. 1, May 2022, pp. 1–17. EBSCOhost, https://doi.org/10.1186/s40249-022-00977-x.

APA

Lv, J., Wu, H., Xu, J., & Liu, J. (2022). Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infectious Diseases of Poverty, 11(1), 1–17. https://doi.org/10.1186/s40249-022-00977-x

Chicago

Lv, Jingjing, Hui Wu, Junjie Xu, and Jiaye Liu. 2022. “Immunogenicity and Safety of Heterologous versus Homologous Prime-Boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine: A Systematic Review.” Infectious Diseases of Poverty 11 (1): 1–17. doi:10.1186/s40249-022-00977-x.